Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)

The summary for the Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional): This Notice of Funding Opportunity (NOFO) invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. More specifically, studies should focus on one or more of the following: i) identifying what environmental or lifestyle exposures are driving the increase in the incidence of non-hereditary EOCs, and how these factors vary by patient demographics; ii) examining the biological mechanisms and host responses that underlie the increase in EOCs; and iii) identifying how those at increased risk of developing EOCs can be identified more effectively.In an effort to streamline the application process and sustain momentum in this critical research area, this NOFO supports both exploratory/developmental and standard research projects through a grant award instrument.

Federal Grant Title:	Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-28-014
Type of Funding:	Grant
CFDA Numbers:	93.113, 93.393
CFDA Descriptions:	Information not provided
Current Application Deadline:	October 11th, 2029
Original Application Deadline:	October 11th, 2029
Posted Date:	October 14th, 2026
Creation Date:	October 14th, 2026
Archive Date:	December 11th, 2029
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 14th, 2026

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16.8 Collaborative International Research Awards.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Grant Announcement Contact: National Cancer Institute (NCI)
[email protected]
[email protected]
Similar Government Grants: • NIH Research Program Projects (Parent P01 Clinical Trial Optional); • Lasker Clinical Research Scholar's Program (Si2/R00 Clinical Trial Optional); • Institutional Mentored Career Development Award (Parent K12) (Clinical Trials Not Allowed); • Predoctoral to Postdoctoral Transition Award (Parent F99/K00 - Clinical Trial Not Allowed); • HEAL Initiative: Limited Competition for the HEALthy Brain and Child Development (HBCD) St...; • Outstanding New Environmental Scientist Award (ONES); • Environmental Health Sciences Core Center Grants; • Leiomyomata Uteri: Basic Science and Translational Research
More Grants from the National Institutes of Health: • Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional); • NIH Research Program Projects (Parent P01 Clinical Trial Optional); • Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R...; • Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028...; • Accelerating Research and Development of Next Generation Vaccines against Malaria - a Mode...